Suppl Table 1 Use of alteplase and management details from randomisation to Day 7

	Non-China	China	P value
Body Weight			
Patients with estimated body weight prior to alteplase	1878/1878 (100)	1419/1419 (100)	
Estimated measurement prior to alteplase use (kg)	71.4 (16.1)	67.6 (11.5)	<0.0001
Patients with direct measured body weight after alteplase use	1673/1878 (89.1)	1297/1419 (91.4)	0.03
Direct measured body weight after alteplase use (kg)	70.7 (16.3)	67.5 (11.5)	<0.0001
Alteplase given			
Any given	1854/1876 (98.8)	1391/1415 (98.3)	0.21
Bolus dose (mg)*	6.4 (2.0)	6.1 (1.1)	<0.0001
Infusion over 60 mins dose (mg)*	46.6 (14.7)	44.5 (12.8)	<0.0001
Time from randomization to treatment (mins)	4.2 (1.5 - 7.5)	9.5 (3.7 - 18.1)	<0.0001
Time from stroke onset to treatment (mins)	146.0 (110.0 - 192.0)	200.0 (160.0 - 235.0)	<0.0001
Management			
Cerebral angiogram undertaken	149/1876 (7.9)	22/1412 (1.6)	<0.0001
Occluded cerebral vessel identified	134/ 148 (90.5)	17/ 22 (77.3)	0.07
Endovascular clot retrieval used	114/ 149 (76.5)	10/ 22 (45.5)	0.002
Any intravenous BP lowering treatment in first 24 hours	408/1866 (21.9)	385/1405 (27.4)	0.0003
Any intravenous BP lowering treatment in days 2-7	277/1854 (14.9)	335/1380 (24.3)	<0.0001
Systolic BP at 24 hours (mmHg)	136.6 (21.1)	136.9 (17.7)	0.65
Intubation and ventilation	119/1854 (6.4)	51/1380 (3.7)	0.0006
Fever occurrence	329/1853 (17.8)	290/1380 (21.0)	0.02
Fever treated	275/1628 (16.9)	243/1236 (19.7)	0.0566
Nasogastric feeding given	345/1853 (18.6)	238/1380 (17.2)	0.32
Patient mobilized by therapist	1159/1853 (62.5)	295/1380 (21.4)	<0.0001
Compression stockings used	229/1852 (12.4)	54/1380 (3.9)	<0.0001
Subcutaneous heparin used	407/1878 (21.7)	220/1419 (15.5)	<0.0001

	Non-China	China	P value
Any antithrombotic agent (antiplatelet or heparin) used in first 24 hours	387/1870 (20.7)	185/1412 (13.1)	<0.0001
Intravenous traditional Chinese medicine administered	8/1853 (0.4)	931/1380 (67.5)	<0.0001
Intravenous steroids administered	24/1853 (1.3)	53/1380 (3.8)	<0.0001
Hemicraniectomy performed	26/1854 (1.4)	9/1380 (0.7)	0.04
Any neurosurgery performed	98/1878 (5.2)	16/1419 (1.1)	<0.0001
Any stroke unit admission	1463/1854 (78.9)	514/1380 (37.2)	<0.0001
Any intensive care unit admission	428/1853 (23.1)	344/1380 (24.9)	0.23
Any rehabilitation given	1135/1854 (61.2)	506/1380 (36.7)	<0.0001
Decision to withdrawal active care	53/1855 (2.9)	32/1380 (2.3)	0.34

*P value is significant

Data are n (%), mean (SD), or median (IQR). The P values are based on Chi-square, T test, or Wilcoxon signed-rank test

BP: blood pressure; NIHSS: The National Institutes of Health Stroke Scale

Suppl Table 2 Major clinical outcomes at 90 days by non-China versus China

Outcome	Event, n(%)	OR (95% CI)	P value	AOR[1] (95% CI)	P value	AOR[2] (95% CI)	P value
Death or disability: mRS score 2 to 6							
Non-China	999/1797 (55.6)	1.0					
China	673/1409 (47.8)	0.73(0.64-0.84)	<0.0001	0.66(0.55-0.79)	<0.0001	0.75(0.6-0.93)	0.01
Death or major disability: mRS score 3 to 6							
Non-China	708/1797 (39.4)	1.0					
China	489/1409 (34.7)	0.82(0.71-0.94)	0.01	0.8(0.66-0.97)	0.02	0.86(0.68-1.08)	0.20
Death during follow-up at 90 days							
Non-China	189/1878 (10.1)						
China	121/1419 (8.5)	0.83(0.66-1.06)	0.13	0.66(0.47-0.92)	0.02	0.5(0.33-0.76)	0.01

AOR: adjusted odds ratio; mRS: modified Rankin Scale; OR: odds ratio

Model 1: adjusted for age, adjusted for age, baseline GCS score, time from onset to randomization (<3 vs. ≥3 hr), sex, baseline systolic blood pressure, pre-morbid mRS (0 or 1), pre-morbid use of aspirin, other antiplatelet agent or warfarin anticoagulant, any history of stroke, coronary artery disease, atrial fibrillation, hypercholesterolemia, randomized treatment (low-dose vs. standard-dose), and stroke subtype

Model 2: model 1+ management factors: intravenous BP lowering treatment at day 1, intubation, fever therapist, stockings, subcutaneous heparin used, intravenous steroids administration, neurosurgery and admission rehabilitation given.

Suppl Table 3 Key secondary outcomes- Symptomatic intracerebral hemorrhage by non-China versus China

	Non-China	China	OR	P value	AOR*	P value
SITS-MOST criteria	27/1878 (1.4)	25/1419 (1.8)	1.23(0.71-2.13)	0.46	1.19(0.59-2.41)	0.63
NINDS criteria	133/1878 (7.1)	96/1419 (6.8)	0.95(0.73-1.25)	0.72	0.94(0.67-1.32)	0.72
ECASS2 criteria	81/1878 (4.3)	61/1419 (4.3)	1(0.71-1.4)	0.98	0.93(0.61-1.44)	0.75
ECASS3 criteria	34/1878 (1.8)	28/1419 (2.0)	1.09(0.66-1.81)	0.73	1.1(0.58-2.12)	0.76
IST-3 criteria	47/1878 (2.5)	37/1419 (2.6)	1.04(0.67-1.61)	0.85	0.98(0.56-1.69)	0.93
Fatal	17/1878 (0.9)	16/1419 (1.1)	1.25(0.63-2.48)	0.53	0.92(0.35-2.47)	0.87
Adjudicated any ICH	355/1878 (18.9)	216/1419 (15.2)	0.77(0.64-0.93)	0.01	0.82(0.65-1.03)	0.08

* adjusted for baseline NIHSS score, pre-morbid use of aspirin, atrial fibrillation, time from onset to treatment and randomized treatment (low-dose vs. standard-dose), and stroke subtype

ECASS: European Co-operative Acute Stroke Study; ICH: intracerebral hemorrhage; IST: International Stroke Trial, NINDS: National Institute of Neurological Disorders and Stroke; OR: odds ratio; SITS-MOST: Safe Implementation of Thrombolysis in Stroke Monitoring Study

Suppl Table 4 Randomised treatment effects on symptomatic intracerebral hemorrhage outcomes by non-China versus China

	Low-dose	Standard-dose	OR(95%CI)	P value for interaction
SITS-MOST criteria				
Non-China	9/ 946 (1.0)	18/ 932 (1.9)	0.49(0.22 -1.09)	0.94
China	8/ 708 (1.1)	17/ 711 (2.4)	0.47(0.2 -1.09)	
NINDS criteria				
Non-China	56/ 946 (5.9)	77/ 932 (8.3)	0.7(0.49 -1)	0.74
China	42/ 708 (5.9)	54/ 711 (7.6)	0.77(0.51 -1.16)	
ECASS2 criteria				
Non-China	30/ 946 (3.2)	51/ 932 (5.5)	0.57(0.36 -0.9)	0.59
China	25/ 708 (3.5)	36/ 711 (5.1)	0.69(0.41 -1.16)	
ECASS3 criteria				
Non-China	11/ 946 (1.2)	23/ 932 (2.5)	0.46(0.23 -0.96)	0.99
China	9/ 708 (1.3)	19/ 711 (2.7)	0.47(0.21 -1.04)	
IST-3 criteria				
Non-China	20/ 946 (2.1)	27/ 932 (2.9)	0.72(0.4 -1.3)	0.51
China	13/ 708 (1.8)	24/ 711 (3.4)	0.54(0.27 -1.06)	
Fatal ICH				
Non-China	5/ 946 (0.5)	12/ 932 (1.3)	0.41(0.14 -1.16)	0.79
China	4/ 708 (0.6)	12/ 711 (1.7)	0.33(0.11 -1.03)	
Adjudicated any ICH				
Non-China	175/ 946 (18.5)	180/ 932 (19.3)	0.95(0.75 -1.19)	0.70
China	102/ 708 (14.4)	114/ 711 (16.0)	0.88(0.66 -1.18)	

CI: confidence interval; ECASS: European Co-operative Acute Stroke Study; IST: International Stroke Trial; NINDS: National Institute of Neurological Disorders and Stroke; OR: odds ratio; SITS-MOST: Safe Implementation of Thrombolysis in Stroke Monitoring Study